Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (33)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chávez, M.
Right arrow Articles by Mazuelos, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chávez, M.
Right arrow Articles by Mazuelos, E. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 697-700
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients

M. Cháveza, S. Bernala, A. Valverdea, M. J. Gutierreza, G. Quindósb and E. Martin Mazuelosa,*

a Servicio de Microbiología Clínica, Hospital Universitario de Valme, E-41014 Sevilla; b Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y Odontología, Universidad del País Vasco, E-48080 Bilbao, Spain

In this report we compare the activity of two new antifungal agents, voriconazole (UK-109,496) and LY303366 with the activities of other antifungals including fluconazole, itraconazole, 5-fluorocytosine (5FC) and amphotericin B against 219 oral Candida spp. isolates from HIV-infected patients. We used the broth microdilution method following the guidelines of the NCCLS. The in-vitro activity of voriconazole (UK-109,496) (MIC90 0.12 mg/L) and LY303366 (CMI90 0.25 mg/L) against clinical isolates of Candida spp. was excellent and comparable with that of amphotericin B (MIC90 0.5 mg/L), and better than those of fluconazole (MIC90 >= 64 mg/L), itraconazole (MIC90 4 mg/L) and 5FC (MIC90 1 mg/L).

* Corresponding author. Tel: +349-5-459-6352; Fax:+349-5-459-6395.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
D. K. Benjamin Jr., T. Driscoll, N. L. Seibel, C. E. Gonzalez, M. M. Roden, R. Kilaru, K. Clark, J. A. Dowell, J. Schranz, and T. J. Walsh
Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections
Antimicrob. Agents Chemother., February 1, 2006; 50(2): 632 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. A. Pfaller, D. J. Diekema, L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and B. P. Goldstein
Effectiveness of Anidulafungin in Eradicating Candida Species in Invasive Candidiasis
Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4795 - 4797.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. C. Serrano, M. Ramirez, D. Morilla, A. Valverde, M. Chavez, A. Espinel-Ingroff, R. Claro, A. Fernandez, C. Almeida, and E. Martin-Mazuelos
A comparative study of the disc diffusion method with the broth microdilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp.
J. Antimicrob. Chemother., May 1, 2004; 53(5): 739 - 742.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. C. Serrano, D. Morilla, A. Valverde, M. Chavez, A. Espinel-Ingroff, R. Claro, M. Ramirez, and E. M. Mazuelos
Comparison of Etest with Modified Broth Microdilution Method for Testing Susceptibility of Aspergillus spp. to Voriconazole
J. Clin. Microbiol., November 1, 2003; 41(11): 5270 - 5272.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. P. Arevalo, A.-J. Carrillo-Munoz, J. Salgado, D. Cardenes, S. Brio, G. Quindos, and A. Espinel-Ingroff
Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method
J. Antimicrob. Chemother., January 1, 2003; 51(1): 163 - 166.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Cuenca-Estrella, E. Mellado, T. M. Diaz-Guerra, A. Monzon, and J. L. Rodriguez-Tudela
Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B
J. Antimicrob. Chemother., September 1, 2000; 46(3): 475 - 477.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.